Wang Long, Zheng Xiuli, Hui Yi, Wang Baojia, Yang Yu, Feng Xianrong, Zhang Tianyao, Ma Li, Zhang Xiaobo
Chengdu University of Traditional Chinese Medicine.
Shaanxi University of Traditional Chinese Medicine, Xianyang, Shaanxi, China.
Medicine (Baltimore). 2019 Aug;98(35):e17053. doi: 10.1097/MD.0000000000017053.
Bronchial asthma is one of the most common chronic diseases in the world and has become a serious public health problem. Combination therapy has become the first choice for clinical treatment of bronchial asthma. In addition to the combined use of routine medication, traditional Chinese medicine as an adjuvant therapy is also considered. Xiaoqinglong Decoction (XQLD) is an effective prescription of traditional Chinese medicine in treating asthma, and there are more and more clinical reports about its combination with western medicine in treating asthma. Therefore, we designed this study protocol to evaluate the adjuvant role of XQLD in the treatment of bronchial asthma.
The following electronic databases will be systematically searched from inception to April 2019: PubMed, EMBASE database, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wan Fang, Chinese Scientific Journals Database (VIP), and China Biology Medicine disc, (CBM). And the following primary outcomes will be tested, including effective rate (ER), pulmonary function (FEV1, PEF, FEV1/FVC), adverse reactions (AR). RevMan5 software will be used for literature quality evaluation and stata14.0 software will be used for data synthesis and analysis.
To evaluate the efficacy and safety of Xiaoqinglong decoction in combination therapy by observing the outcomes of efficacy, adverse reactions and pulmonary function.
This study protocol will be used to evaluate the efficacy and safety of XQLD in combination with conventional drugs in the treatment of bronchial asthma, as well as the adjuvant role of XQLD in combination.
CRD42019133549.
支气管哮喘是世界上最常见的慢性病之一，已成为严重的公共卫生问题。联合治疗已成为支气管哮喘临床治疗的首选。除了联合使用常规药物外，中药作为辅助治疗也被考虑。小青龙汤是治疗哮喘的一种有效的中药方剂，关于其与西药联合治疗哮喘的临床报道越来越多。因此，我们设计了本研究方案，以评估小青龙汤在支气管哮喘治疗中的辅助作用。
从数据库建立至2019年4月，将对以下电子数据库进行系统检索：PubMed、EMBASE数据库、Cochrane图书馆、中国知网（CNKI）、万方、维普中文科技期刊数据库（VIP）和中国生物医学文献数据库（CBM）。将检测以下主要指标，包括有效率（ER）、肺功能（FEV1、PEF、FEV1/FVC）、不良反应（AR）。将使用RevMan5软件进行文献质量评估，使用stata14.0软件进行数据合成与分析。
通过观察疗效、不良反应和肺功能结果，评估小青龙汤在联合治疗中的疗效和安全性。
本研究方案将用于评估小青龙汤联合常规药物治疗支气管哮喘的疗效和安全性，以及小青龙汤联合用药的辅助作用。
PROSPERO注册号：CRD42019133549。
